Nouvelles règles d'utilisation des bisphosphonates dans le myélome multiple = New guidelines for the use of bisphosphonates in multiple myelomaMACRO, Margaret.Hématologie (Montrouge). 2008, Vol 14, Num 3, pp 244-247, issn 1264-7527, 4 p.Article

Immunoglobuline monoclonale = Monoclonal gammopathiesMACRO, Margaret.La Revue du praticien (Paris). 2008, Vol 58, Num 18, pp 2071-2077, issn 0035-2640, 7 p.Article

IgM multiple myeloma: More on a rare and heterogeneous diseaseCABRERA, Quentin; CHANTEPIE, Sylvain; SALAUN, Veronique et al.American journal of hematology. 2011, Vol 86, Num 8, pp 717-718, issn 0361-8609, 2 p.Article

Skin manifestations in CD4+, CD56+ malignanciesPENVEN, Katell; MACRO, Margaret; SALAÜN, Véronique et al.EJD. European journal of dermatology. 2003, Vol 13, Num 2, pp 161-165, issn 1167-1122, 5 p.Article

Amylose AL avec atteinte de l'artère temporale évoquant une artérite giganto-cellulaireAUDEMARD, Alexandra; BOUTEMY, Jonathan; GALATEAU-SALLE, Françoise et al.Revue du rhumatisme (Ed. française). 2012, Vol 79, Num 3, pp 278-280, issn 1169-8330, 3 p.Article

Epidemiology of Monoclonal Gammopathy of Undetermined Significance (MGUS): The experience from the specialized registry of hematologic malignancies of Basse-Normandie (France)CABRERA, Quentin; MACRO, Margaret; HEBERT, Benedikte et al.Cancer epidemiology (Print). 2014, Vol 38, Num 4, pp 354-356, issn 1877-7821, 3 p.Article

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)AVET-LOISEAU, Hervé; LELEU, Xavier; KOLB, Brigitte et al.Journal of clinical oncology. 2010, Vol 28, Num 30, pp 4630-4634, issn 0732-183X, 5 p.Article

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteCOIFFIER, Bertrand; THIEBLEMONT, Catherine; BELHADJ, Karim et al.Blood. 2010, Vol 116, Num 12, pp 2040-2045, issn 0006-4971, 6 p.Article

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years : Long-term results of a randomized control trial from the group myelome-autogreffeFERMAND, Jean-Paul; KATSAHIAN, Sandrine; BELANGER, Coralie et al.Journal of clinical oncology. 2005, Vol 23, Num 36, pp 9227-9233, issn 0732-183X, 7 p.Article

Impact of Initial FDG-PET/CT and Serum-Free Light Chain on Transformation of Conventionally Defined Solitary Plasmacytoma to Multiple MyelomaFOUQUET, Guillemette; GUIDEZ, Stéphanie; BERTHON, Céline et al.Clinical cancer research (Print). 2014, Vol 20, Num 12, pp 3254-3260, issn 1078-0432, 7 p.Article

Hematogones: a new prognostic factor for acute myeloblastic leukemiaCHANTEPIE, Sylvain P; SALAÜN, Veronique; PARIENTI, Jean-Jacques et al.Blood. 2011, Vol 117, Num 4, pp 1315-1318, issn 0006-4971, 4 p.Article

Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term SurvivalAVET-LOISEAU, Hervé; ATTAL, Michel; VOOG, Eric et al.Journal of clinical oncology. 2012, Vol 30, Num 16, pp 1949-1952, issn 0732-183X, 4 p.Article

Comparison of 200 mg/m² melphalan and 8 Gy total body irradiation plus 140 mg/m² melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trialMOREAU, Philippe; FACON, Thierry; JAUBERT, Jérome et al.Blood. 2002, Vol 99, Num 3, pp 731-735, issn 0006-4971Article